Table 1. Cloning efficiency and functional retention of T cell clones.
| Stimulus | T cell Subset | Wells Seeded | Established Clonesa | IFN-γ+ clonesb | Functional clonesd |
| LCL | CD4+ | 234 | 62 (26%) | 5/5c | 15/65 (23%) |
| CD8+ | 246 | 116 (47%) | 9/107 (8%) | 15/126 (12%) | |
| CMV pp65 | CD4+ | 250 | 87 (35%) | 41/87 (47%) | – |
| CD8+ | 230 | 66 (29%) | 19/66 (29%) | – | |
| A02-M | CD4+ | 114 | 32 (28%) | 19/31 (61%) | – |
| CD8+ | 162 | 57 (35%) | 23/63 (37%) | 23/63 (37%) | |
| D14-M | CD4+ | ND | ND | ND | ND |
| CD8+ | 288 | 227 (79%) | 221/288 (77%) | 267/288 (93%) |
Number of growing clones, percentage of wells seeded in brackets.
Number of clones producing>100 pg/ml more IFN-γ in response to autologous/antigen loaded autologous targets than to control targets, as a fraction of total clones tested; percentage in brackets. In some cases clones that did not proliferate long term were tested, so the denominator is different to the number of established clones.
CD4+ clones from LCL stimulation were pre-selected from a subset which were positive for antigen-stimulated proliferation, and thus may not be representative of the 62 proliferating clones.
Clones were tested for cytolytic activity (CD8+ clones from LCL and melanoma stimulation only), IFN-γ production (CD4+ and CD8+ clones from each stimulation), or proliferation (CD4+ LCL clones only). Data represent number of clones with any significant response to autologous antigen, as a fraction of total number of clones tested.
ND, not done; – indicates no test additional to IFN-γ production was performed.